Less risky.: Due to sampling error and the relative risk of biopsy, PROMETHEUS FIBROSpect II testing is useful for initial patient evaluation and when biopsy is contraindicated or refused. The short answer is it is less risky, but a liver biopsy may still be needed, it is just an alternative, different doctors have different preferences.
Answered 6/28/2014
3.9k views
Less invasive: Knowing the amount of inflammation and level of fibrosis in the liver can help in deciding what hepatitis therapy a patient needs. Though the liver biopsy is considered the gold standard, the newer generation of tests, when taken in clinical context, can estimate the amount of inflammation and level of fibrosis in the liver.
Answered 6/28/2014
3.9k views
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
5 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question